JP2023514080A - 幹細胞を含む心膜内注入用組成物およびその用途 - Google Patents
幹細胞を含む心膜内注入用組成物およびその用途 Download PDFInfo
- Publication number
- JP2023514080A JP2023514080A JP2022544853A JP2022544853A JP2023514080A JP 2023514080 A JP2023514080 A JP 2023514080A JP 2022544853 A JP2022544853 A JP 2022544853A JP 2022544853 A JP2022544853 A JP 2022544853A JP 2023514080 A JP2023514080 A JP 2023514080A
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- composition
- intrapericardial
- cells
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 167
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000001802 infusion Methods 0.000 title claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000000747 cardiac effect Effects 0.000 claims description 117
- 239000004005 microsphere Substances 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 36
- 239000007924 injection Substances 0.000 claims description 32
- 238000002347 injection Methods 0.000 claims description 32
- 208000010125 myocardial infarction Diseases 0.000 claims description 29
- 239000000017 hydrogel Substances 0.000 claims description 22
- 208000031225 myocardial ischemia Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002107 myocardial effect Effects 0.000 claims description 7
- 108010073385 Fibrin Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 208000023589 ischemic disease Diseases 0.000 claims description 6
- -1 MatrigelTM Polymers 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 15
- 210000003516 pericardium Anatomy 0.000 abstract description 5
- 210000005003 heart tissue Anatomy 0.000 description 22
- 238000010171 animal model Methods 0.000 description 20
- 238000002054 transplantation Methods 0.000 description 18
- 230000004217 heart function Effects 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 238000011084 recovery Methods 0.000 description 10
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 210000005240 left ventricle Anatomy 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 4
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical compound CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000535 fibrinogen concentrate Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
実施例1:心筋梗塞動物モデルの製作および心臓幹細胞の移植
すべての動物の取り扱いおよび手続きは、韓国の梨花女子大学校の動物管理および使用委員会の承認を得た研究プロトコルによって行った(IACUC番号:18-073)。心筋梗塞(myocardial infarction,MI)動物モデルを製作するために、10~12週齢のBALB/c雄マウスを3%イソフルラン(isoflurane)を用いて麻酔させた。また、開胸術を通じて心臓を確認し、近位左前下行冠動脈(proximal left anterior descending coronary artery)を7-0 Prolene縫合糸(Ethicon)を用いて結紮(ligation)させて、心筋梗塞動物モデルを製作した。
心臓幹細胞(cardiac stem cells,CSCs)の微小球(spheroid)を製造するために、一次的にヒト由来心臓幹細胞を培養液(10%(v/v)ウシ胎仔血清(fetal bovine serum,FBS)、10ng/ml epidermal growth factor(EGF)、2ng/ml basic fibroblast growth factor(bFGF)、10ng/ml insulin-like growth factor-1(IGF-1)および1%(v/v)antibiotics-antimycoplasmic reagent(AA)がDMEM:F-12(1:1 volume ratio))が収容されたT-75フラスコに接種し、5%CO2、37℃培養器で密集度(confluency)が80%に到達するまで培養した後、継代培養した。11回継代培養した心臓幹細胞をそれぞれ2.5×105、5×105、7.5×105、1×106 cells/mLの濃度になるように、1%(v/v)子牛の血清(calf serum,CS)、0.1%(v/v)DMSO、および50μg/mLのアスコルビン酸(ascorbic acid)が添加されたDMEM with low glucoseが収容されているUltra-Low Attachment Surface 6 well culture plate(Corning)に接種し、3日間培養して、心臓幹細胞微小球を製作した。それぞれの細胞数によって生成された微小球のサイズは、光学顕微鏡で生成された微小球の直径を測定して示した。その結果は、図2Cおよび図2Dに示した。また、形成された微小球をLIVE/DEAD Viability/Cytotoxicity Assay Kit(Molecular ProbesTM)を用いて染色した後、微小球内に含まれている細胞の数による細胞の生存程度を確認した。その結果は、図2Aおよび図2Bに示した。
ヒドロゲルを用いた心膜内注入用組成物を製造するために、7.5μLのトロンビン溶液(0.5IU/mL)に5×105cells/mLの心臓幹細胞または5×105cells/mLの心臓幹細胞を用いて製造された心臓幹細胞微小球を懸濁し、前記懸濁液に7.5μLのフィブリノゲン濃縮物(0.2mg/mL)を添加し、反応させて、ゲル形態の心臓幹細胞微小球心膜内注入用組成物を製作した。
心臓幹細胞微小球を移植するために、一次的に実施例1と同じ方法で心筋梗塞動物モデルを製作した。また、製作された心筋梗塞動物モデルに5×105cells/mLの心臓幹細胞、5×105cells/mLの心臓幹細胞を用いて製造された心臓幹細胞微小球(CSC spheroid)、または実施例3と同じ方法で製造されたヒドロゲルに含まれている心臓幹細胞(CSC+gel)、またはヒドロゲルに含まれている心臓幹細胞微小球(CSC spheroid-Gel)をそれぞれ15μLずつ心膜腔(pericardial cavity)に27ゲージのハミルトンシリンジを用いて試料を注射した。以下、すべての実験において「Sham」グループは、何らの処置もしない正常マウスであり、「Control」グループは、心筋梗塞動物モデルであり、「Saline」グループは、塩類溶液を同量注射した対照群であり、「CSC」グループは、心臓幹細胞を注射した実験群であり、「CSC spheroid」グループは、心臓幹細胞微小球を同量注射した実験群であり、「CSC+gel」グループは、ヒドロゲルに含まれている心臓幹細胞を同量注射した実験群であり、「CSC spheroid-Gel」グループは、ヒドロゲルに含まれている心臓幹細胞微小球を同量注射した実験群を示す。
5.1.動物モデルの生存率の確認
実施例4と同じ方法で移植された心筋梗塞動物モデルの生存率をKaplan-Meierカーブで確認した。以後、すべての実験は、最小3回以上繰り返し行い、結果は、平均値±標準偏差で示した。統計的有意性は、2つのグループ間には、Student’s t-testで確認し、3つ以上のグループ間には、two-way ANOVA後にBonferroni’s comparison testを用いて確認した。p<0.05であれば、統計的に有意性があると判断した。その結果は、図3に示した。
移植された心臓幹細胞微小球による虚血性心疾患の治療効果を確認するために、移植された細胞の生着有無をDiRを用いて確認した。より詳しくは、IVIS-100 imaging system(Caliper Life Science)を用いて生きている動物モデルの蛍光を観察した。蛍光強度は、photons/cm2 per secondで算出した。また、心臓組織の染色のために、心臓幹細胞微小球を移植した動物モデルを4週後に安楽死させた後に心臓組織を抽出した。また、抽出された心臓組織は、4%パラホルムアルデヒド溶液を用いて固定させ、パラフィンを用いてembeddingさせた後、0.4μmの厚さに切って、心臓組織切片を製造して使用した。その結果は、図4~図6に示した。
移植された心臓幹細胞微小球による虚血性心疾患の治療効果を確認するために、移植された細胞の心血管分化効率を確認した。心血管分化効率を確認するために、前記実施例5.2と同じ方法で準備した心臓組織切片をα-SA(α-sarcomeric actinin)抗体(Abcam)またはα-SMA(α-smooth muscle actin)抗体(Abcam)、そして、DAPIを用いて染色し、蛍光顕微鏡を用いて観察した。その結果は、図7に示した。
心臓幹細胞微小球の移植による心臓再生効果を確認するために、前記実施例5.2と同じ方法で準備した心臓組織切片をcTnI(cardiac troponin I)抗体(Abcam)、α-SMA抗体(Abcam)、そして、DAPIを用いて染色し、蛍光顕微鏡を用いて観察した。その結果を図8および図9に示した。
心臓幹細胞または心臓幹細胞微小球の移植による治療効果を確認するために、心臓機能を心超音波を用いて確認した。より詳しくは、マウスを麻酔させ、37℃のheating padの上に載置し、echocardiography probe(MS-400)が装着されたVEVO2100micro-ultrasound system(Visual Sonics)を用いて心超音波を実施した。左心室(LV)は、parasternal long-axisおよびM-mode tracingsを全部イメージ化し、2次元心超音波のcine loopsを記録した。駆出率(ejection fraction,EF)、短縮率(fractional shortening,FS)、左心室拡張末期径(left ventricle end diastolic diameter,LVEDD)、および左心室収縮末期径(left ventricle end systolic diameter,LVESD)値をそれぞれ測定し、測定時期は、心筋梗塞の誘導前、心筋梗塞の誘導後、そして、心臓幹細胞の移植後1週間後、2週間後、3週間後および4週間後それぞれに測定した。その結果を図12に示した。
ヒドロゲルに含まれている心臓幹細胞または心臓幹細胞微小球の移植による治療効果を確認するために、実施例5.5と同じ方法で心臓機能を心超音波を用いて確認した。「Gel」グループは、フィブリンゲルのみを同量注射した対照群である。その結果を図13に示した。
Claims (11)
- 幹細胞を有効成分として含む、心膜内注入用組成物。
- 前記幹細胞は、幹細胞微小球であることを特徴とする請求項1に記載の心膜内注入用組成物。
- 前記幹細胞微小球は、10μm~500μmの直径を有することを特徴とする請求項2に記載の心膜内注入用組成物。
- 前記幹細胞微小球は、微小球当たり100~5000個の細胞を含んでいることを特徴とする請求項2に記載の心膜内注入用組成物。
- 前記心膜内注入用組成物は、ヒドロゲル(hydrogel)をさらに含むことを特徴とする請求項1に記載の心膜内注入用組成物。
- 前記ヒドロゲルは、コラーゲン(collagen)、ゼラチン(gelatin)、コンドロイチン(chondroitin)、ヒアルロン酸(hyaluronic acid)、アルギン酸(alginic acid)、マトリゲル(MatrigelTM)、キトサン(chitosan)、ペプチド(peptide)、フィブリン(fibrin)、PGA(polyglycolic acid)、PLA(polylactic acid)、PEG(polyethylene glycol)およびポリアクリルアミド(polyacrylamide)からなる群から選ばれたいずれか一つ以上であることを特徴とする請求項5に記載の心膜内注入用組成物。
- 前記幹細胞は、心筋由来幹細胞、骨髄由来幹細胞、脂肪由来幹細胞、臍帯血由来幹細胞、逆分化幹細胞、血管内皮前駆細胞、造血幹細胞、神経幹細胞、および心臓前駆細胞からなる群から選ばれたいずれか一つ以上であることを特徴とする請求項1に記載の心膜内注入用組成物。
- 請求項1から7のいずれか1項に記載の心膜内注入用組成物を有効成分として含む、虚血性心疾患の予防または治療用薬学的組成物。
- 前記虚血性心疾患は、心筋梗塞または狭心症であることを特徴とする請求項8に記載の薬学的組成物。
- 請求項1から7のいずれか1項に記載の心膜内注入用組成物を有効成分として含む組成物を個体に投与する段階を含む虚血性疾患の予防または治療方法。
- 請求項1から7のいずれか1項に記載の心膜内注入用組成物を有効成分として含む組成物の虚血性疾患の予防または治療用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0012963 | 2020-02-04 | ||
KR20200012963 | 2020-02-04 | ||
KR10-2021-0015522 | 2021-02-03 | ||
KR1020210015522A KR20210099527A (ko) | 2020-02-04 | 2021-02-03 | 줄기세포를 포함하는 심막 내 주입용 조성물 및 이의 용도 |
PCT/KR2021/001499 WO2021158045A1 (ko) | 2020-02-04 | 2021-02-04 | 줄기세포를 포함하는 심막 내 주입용 조성물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023514080A true JP2023514080A (ja) | 2023-04-05 |
Family
ID=77200292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022544853A Pending JP2023514080A (ja) | 2020-02-04 | 2021-02-04 | 幹細胞を含む心膜内注入用組成物およびその用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230063104A1 (ja) |
EP (1) | EP4101440A4 (ja) |
JP (1) | JP2023514080A (ja) |
WO (1) | WO2021158045A1 (ja) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10281478B2 (en) * | 2000-04-06 | 2019-05-07 | Wayne P. Franco | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs |
ES2373551T3 (es) * | 2003-02-20 | 2012-02-06 | Cytori Therapeutics, Inc. | Métodos para usar células derivadas de tejido adiposo en el tratamiento de afecciones cardiovasculares. |
PL1885382T3 (pl) * | 2005-05-25 | 2011-09-30 | Cytori Therapeutics Inc | Sposoby stosowania komórek pochodzących z tkanki tłuszczowej w leczeniu stanów układu sercowo-naczyniowego |
EP2134182A4 (en) * | 2005-11-08 | 2010-01-06 | Univ South Florida | IMPROVED STEM CELL TREATMENT METHOD FOR VASCULAR REPAIR |
WO2011031299A1 (en) * | 2009-08-28 | 2011-03-17 | Mount Sinai School Of Medicine Of New York University | Intrapericardial injections |
KR101226629B1 (ko) * | 2010-12-08 | 2013-01-28 | 이화여자대학교 산학협력단 | 섬유형 다공성 삼차원 지지체를 포함하여 구성되는 손상된 조직 재생용 패치 |
KR101389850B1 (ko) * | 2012-05-04 | 2014-04-29 | 이화여자대학교 산학협력단 | 심장전구세포의 배양방법 및 그 용도 |
WO2014093836A1 (en) * | 2012-12-13 | 2014-06-19 | University Of Georgia Research Foundation, Inc. | Ossification-inducing composition and methods of use thereof |
JP5862915B2 (ja) * | 2013-05-31 | 2016-02-16 | iHeart Japan株式会社 | ハイドロゲルを組み込んだ積層化細胞シート |
IL246608A0 (en) * | 2016-07-05 | 2016-09-29 | Holzer Asher | Preparations and methods for treating heart disease |
KR101915367B1 (ko) | 2016-12-20 | 2018-11-05 | 인제대학교 산학협력단 | 심장줄기세포의 다층세포시트 및 이의 제조방법 |
KR102182513B1 (ko) * | 2017-06-30 | 2020-11-25 | 인제대학교 산학협력단 | 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도 |
-
2021
- 2021-02-04 WO PCT/KR2021/001499 patent/WO2021158045A1/ko unknown
- 2021-02-04 EP EP21750964.5A patent/EP4101440A4/en active Pending
- 2021-02-04 US US17/759,926 patent/US20230063104A1/en active Pending
- 2021-02-04 JP JP2022544853A patent/JP2023514080A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021158045A1 (ko) | 2021-08-12 |
EP4101440A1 (en) | 2022-12-14 |
US20230063104A1 (en) | 2023-03-02 |
EP4101440A4 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10639335B2 (en) | Pluripotent stem cell that induces repair and regeneration after myocardial infarction | |
US20020061587A1 (en) | Methods and compositions for the repair and/or regeneration of damaged myocardium | |
Tang et al. | Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction | |
US11969459B2 (en) | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure | |
JP2008537942A (ja) | 心疾患のための処置 | |
CN109589337B (zh) | 心肌细胞制剂及其制备方法和应用 | |
US11692171B2 (en) | Preparation method of human-derived cardiac stem cell spheroid and use thereof | |
JP2023514080A (ja) | 幹細胞を含む心膜内注入用組成物およびその用途 | |
KR20210099527A (ko) | 줄기세포를 포함하는 심막 내 주입용 조성물 및 이의 용도 | |
Law et al. | Myoblast therapies constitute a safe and efficacious platform technology of regenerative medicine for the human health industry | |
Pendyala et al. | Cellular cardiomyoplasty and cardiac regeneration | |
KR102088767B1 (ko) | 혼합물 4f를 이용한 줄기세포 생물학적 활성 증가용 조성물 | |
US10813955B2 (en) | Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells | |
Širmenis et al. | Recovery of infarcted myocardium in an in vivo experiment | |
KR101903964B1 (ko) | 간세포의 재생 증대를 위한 중간엽 줄기세포의 제조방법 및 이를 이용한 간 경화 치료용 조성물 | |
EP3027201B1 (en) | Glycosylated protein of an extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof | |
Fang | INJECTABLE ALGINATE HYDROGELS WITH GROWTH FACTORS/LIVING STEM CELLS FOR MYOCARDIAL INFARCTION REPAIR | |
CETIN et al. | THE EFFECT OF MICROENVIRONMENT ON CELL DIFFERENTIATION IN STEM CELL APPLICATIONS | |
KR20240054878A (ko) | 3d 심장 세포 스페로이드 | |
Gojo et al. | Cardiac Regenerative Medicine Cellular Therapy and Tissue Engineering | |
WO2013045963A1 (en) | A pharmaceutical composition for the treatment of stem cells | |
JP2018145114A (ja) | 血管内皮障害の予防及び/又は治療剤 | |
Orlic et al. | Stem Cell/Myoblast Transplantation for Myocardial Regeneration | |
Beeres | Cardiac regeneration in 2006: Barcelona, 4 September 2006 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230825 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240412 |